Diagnostics and age-related evolution of Lennox–Gastaut syndrome. Management in diverse patient age periods

Lennox–Gastaut syndrome is an epileptic encephalopathy with onset in childhood. The classical triad of diagnostic criteria is well known: 1) presence of various types of refractory epileptic seizures (tonic, atypical absences, myoclonic, tonic/atonic drop attacks, generalized tonic-clonic, focal); 2) cognitive disorders with frequent behavioral disorders (not always evident by the beginning of epileptic seizures); 3) generalized, slow (≤2.5 Hz) spike-wave activity of wakefulness and generalized paroxysmal fast activity on sleep electroencephalogram. Despite the seizure onset usually occurring before the age of 8 (peak at 3–5) years old, the Lennox–Gastaut syndrome is often featured with a lifelong course. Many patients with this syndrome suffer from refractory epilepsy in adulthood, however, not always being provided a proper syndromological diagnosis. Expanding the criteria to diagnose the Lennox–Gastaut syndrome discussed here would allow to choose a proper treatment algorithm. Rufinamide is the drug of the second choice in the adjunctive therapy of epileptic seizures associated with Lennox–Gastaut syndrome. However, a pediatric-to-adult clinic transition of patients with Lennox–Gastaut syndrome may pose some obstacles. Herein, an effective patient management requires not only seizure control, but also improvement of patient's quality of life by influencing cognitive and behavioral issues, sleep disorders, disability (both physical and social), educational problems and employment.

1. Karlov V.A. Epilepsy in children and adult women and men. A guide for doctors. 2nd ed. Мoscow: Binom; 2019: 221–8 (in Russ.).

2. Mukhin K.Yu. Clinical and encephalographic changes at Lennox– Gastaut syndrome. Russian Journal of Child Neurology. 2015; 10 (2): 19–31 (in Russ.). https://doi.org/10.17650/2073-8803-2015-10-2-19-31.

3. Asadi-Pooya A.A. Lennox–Gastaut syndrome: a comprehensive review. Neurol Sci. 2018; 39 (3): 403–14. https://doi.org/10.1007/s10072-017- 3188-y.

4. Camfield P.R. Definition and natural history of lennox-gastaut syndrome. Epilepsia. 2011; 52 (Suppl. 5): 3–9. https://doi.org/10.1111/ j.1528-1167.2011.03177.x.

5. Samanta D. Management of Lennox–Gastaut syndrome beyond childhood: a comprehensive review. Epilepsy Behav. 2021; 114 (Pt. A): 107612. https://doi.org/10.1016/j.yebeh.2020.107612.

6. Trevathan E., Murphy C.C., Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia. 1997; 38 (12): 1283–8. https://doi. org/10.1111/j.1528-1157.1997.tb00065.x.

7. Specchio N., Wirrell E.C., Scheffer I.E., et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022; 63 (6): 1398–442. https://doi.org/10.1111/epi.17241.

8. Belousova E.D., Gorchanova Z.K., Dorofeeva M.Iu. Why the diagnosis of Lennox–Gastaut syndrome is a rare one? The Korsakov’s Journal of Neurology and Psychiatry. 2019; 119 (11-2): 41–7. https://doi.org/10.17116/jnevro201911911241.

9. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014; 95 (4): 360–70. https://doi.org/10.1016/j.ajhg.2014.08.013.

10. Ferlazzo E., Adjien C.K., Guerrini R., et al. Lennox–Gastaut syndrome with late-onset and prominent reflex seizures in trisomy 21 patients. Epilepsia. 2009; 50 (6): 1587–95. https://doi. org/10.1111/j.1528-1167.2008.01944.x.

11. Cross J.H., Auvin S., Falip M., et al. Expert opinion on the management of Lennox–Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017; 8: 505. https://doi.org/10.3389/ fneur.2017.00505.

12. Hughes J.R., Patil V.K. Long-term electro-clinical changes in the Lennox–Gastaut syndrome before, during, and after the slow spike-wave pattern. Clin Electroencephalogr. 2002; 33 (1): 1–7. https://doi.org/10.1177/155005940203300103.

13. Roger J., Remy C., Bureau M., et al. Lennox–Gastaut syndrome in the adult. Rev Neurol (Paris). 1987; 143 (5): 401–5 (in French).

14. Oguni H., Hayashi K., Osawa M. Long-term prognosis of Lennox– Gastaut syndrome. Epilepsia. 1996; 37 (Suppl. 3): 44–7. https://doi.org/10.1111/j.1528-1157.1996.tb01820.x.

15. Ferlazzo E., Nikanorova M., Nikaronova M., et al. Lennox–Gastaut syndrome in adulthood: clinical and EEG features. Epilepsy Res. 2010; 89 (2–3): 271–7. https://doi.org/10.1016/j.eplepsyres.2010.01.012.

16. Harden C., Tomson T., Gloss D., et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017; 88 (17): 1674–80. https://doi.org/10.1212/WNL.0000000000003685.

17. Yagi K. Evolution of Lennox–Gastaut syndrome: a long-term longitudinal study. Epilepsia. 1996; 37 (Suppl. 3): 48–51. https://doi.org/10.1111/j.1528-1157.1996.tb01821.x.

18. Montouris G., Aboumatar S., Burdette D., et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox–Gastaut syndrome in adult patients. Epilepsy Behav. 2020; 110: 107146. https://doi.org/10.1016/j.yebeh.2020.107146.

19. Camfield P., Camfield C. Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study. Epilepsia. 2007; 48 (6): 1128–32. https://doi.org/10.1111/ j.1528-1167.2007.01072.x.

20. Pujar S., Calvert S., Cortina-Borja M., et al. Statistical process control (SPC) – a simple objective method for monitoring seizure frequency and evaluating effectiveness of drug interventions in refractory childhood epilepsy. Epilepsy Res. 2010; 91 (2–3): 205–13. https://doi.org/10.1016/j.eplepsyres.2010.07.013.

21. Hancock E.C., Cross J.H. Treatment of Lennox–Gastaut syndrome. Cochrane Database Syst Rev. 2013; 2013 (2): CD003277. https://doi.org/10.1002/14651858.CD003277.pub3.

22. Adab N., Kini U., Vinten J., et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004; 75 (11): 1575–83. https://doi.org/10.1136/jnnp.2003.029132.

23. Meador K. Valproate poses risk to unborn child. Epilepsy Curr. 2005; 5 (3): 116–7. https://doi.org/10.1111/j.1535-7511.2005.05305.x.

24. Morrow J., Russell A., Guthrie E., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006; 77 (2): 193–8. https://doi.org/10.1136/jnnp.2005.074203.

25. Tomson T., Marson A., Boon P., et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015; 56 (7): 1006–19. https://doi.org/10.1111/epi.13021.

26. Motte J., Trevathan E., Arvidsson J.F., et al. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N Engl J Med. 1997; 337 (25): 1807–12. https://doi.org/10.1056/NEJM199712183372504.

27. Eriksson A.S., Nergårdh A., Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia. 1998; 39 (5): 495–501. https://doi.org/10.1111/j.1528-1157.1998.tb01411.x.

28. Yuen A.W., Land G., Weatherley B.C., Peck A.W. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992; 33 (5): 511–3. https://doi.org/10.1111/j.1365-2125.1992.tb04079.x.

29. Glauser T., Kluger G., Sachdeo R., et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology. 2008; 70 (21): 1950–8. https://doi.org/10.1212/01.wnl.0000303813.95800.0d.

30. Kluger G., Glauser T., Krauss G., et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand. 2010; 122 (3): 202–8. https://doi. org/10.1111/j.1600-0404.2010.01334.x.

31. McMurray R., Striano P. Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide. Neurol Ther. 2016; 5 (1): 35–43. https://doi.org/10.1007/ s40120-016-0041-9.

32. Sharawat I.K., Panda P.K., Panda P., Dawman L. Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: a systematic review and meta-analysis. Seizure. 2021; 91: 296–307. https://doi.org/10.1016/j.seizure.2021.07.004.

33. Sachdeo R.C., Glauser T.A., Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999; 52 (9): 1882–7. https://doi.org/10.1212/ wnl.52.9.1882.

34. Glauser T.A., Levisohn P.M., Ritter F., Sachdeo R.C. Topiramate in Lennox–Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia. 2000; 41 (Suppl. 1): S86–90. https://doi. org/10.1111/j.1528-1157.2000.tb01563.x.

35. Ng Y.T., Conry J.A., Drummond R., et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011; 77 (15): 1473–81. https://doi.org/10.1212/WNL.0b013e318232de76.

36. Conry J.A., Ng Y.T., Kernitsky L., et al. Stable dosages of clobazam for Lennox–Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014; 55 (4): 558–67. https://doi.org/10.1111/epi.12561.

37. Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001; 33 (4): 289–94. https://doi.org/10.1097/ 00004836-200110000-00006.

38. Lemmon M.E., Terao N.N., Ng Y.T., et al. Efficacy of the ketogenic diet in Lennox–Gastaut syndrome: a retrospective review of one institution’s experience and summary of the literature. Dev Med Child Neurol. 2012; 54 (5): 464–8. https://doi. org/10.1111/j.1469-8749.2012.04233.x.

39. Bergqvist A.G. Long-term monitoring of the ketogenic diet: do’s and don’ts. Epilepsy Res. 2012; 100 (3): 261–6. https://doi.org/10.1016/j. eplepsyres.2011.05.020.

40. Chambers A., Bowen J.M. Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis. Ont Health Technol Assess Ser. 2013; 13 (18): 1–37.

41. Frost M., Gates J., Helmers S.L., et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox–Gastaut syndrome. Epilepsia. 2001; 42 (9): 1148–52. https://doi. org/10.1046/j.1528-1157.2001.23900.x.

42. Morris G.L. 3rd, Gloss D., Buchhalter J., et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81 (16): 1453–9. https://doi.org/10.1212/WNL.0b013e3182a393d1.

43. Shahwan A., Bailey C., Maxiner W., Harvey A.S. Vagus nerve stimulation for refractory epilepsy in children: more to VNS than seizure frequency reduction. Epilepsia. 2009; 50 (5): 1220–8. https://doi.org/10.1111/j.1528-1167.2008.01940.x.

44. Rolston J.D., Englot D.J., Wang D.D., et al. Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: a systematic review. Epilepsy Behav. 2015; 51: 13–7. https://doi.org/10.1016/j.yebeh.2015.06.001.

45. Instructions for the medical use of Inovelon® (rufinamide). LP-002841. Available at: https://grls.rosminzdrav.ru/Grls_View_v2. aspx?routingGuid=adca280c-839d-46b2-b347-543c4c0a6ef6 (in Russ.) (accessed 05.07.2022).

46. Rajendran S., Iyer A. Epilepsy: addressing the transition from pediatric to adult care. Adolesc Health Med Ther. 2016; 7: 77–87. https://doi.org/10.2147/AHMT.S79060.

47. Gibson P.A. Lennox–Gastaut syndrome: impact on the caregivers and families of patients. J Multidiscip Healthc. 2014; 7: 441–8. https://doi.org/10.2147/JMDH.S69300.

48. Strzelczyk A., Schubert-Bast S. Expanding the treatment landscape for Lennox–Gastaut syndrome: current and future strategies. CNS Drugs. 2021; 35 (1): 61–83. https://doi.org/10.1007/s40263-020- 00784-8.

49. Camfield P.R., Gibson P.A., Douglass L.M. Strategies for transitioning to adult care for youth with Lennox–Gastaut syndrome and related disorders. Epilepsia. 2011; 52 (Suppl. 5): 21–7. https://doi.org/10.1111/ j.1528-1167.2011.03179.x.

50. Devinsky O. What do you do when they grow up? Approaches to seizures in developmentally delayed adults. Epilepsia. 2002; 43 (Suppl. 3): 71–9. https://doi.org/10.1046/j.1528-1157.43.s.3.2.x.

51. Glauser T.A. Following catastrophic epilepsy patients from childhood to adulthood. Epilepsia. 2004; 45 (Suppl. 5): 23–6. https://doi. org/10.1111/j.0013-9580.2004.05005.x.

52. Warnell P. The transition experience of epilepsy patients/families: results of a telephone survey. Axone. 1998; 20 (2): 31–3.

53. Hayes S.M., Melin J.D., Dupuis M., et al. Assessing the true learning needs of health care professionals in epilepsy care. Epilepsy Behav. 2007; 11 (3): 434–41. https://doi.org/10.1016/j. yebeh.2007.08.006.

54. Camfield C., Camfield P. Twenty years after childhood-onset symptomatic generalized epilepsy the social outcome is usually dependency or death: a population-based study. Dev Med Child Neurol. 2008; 50 (11): 859–63. https://doi. org/10.1111/j.1469-8749.2008.03165.x.

55. Miller S.M., Chan F. Predictors of life satisfaction in individuals with intellectual disabilities. J Intellect Disabil Res. 2008; 52 (12): 1039–47. https://doi.org/10.1111/j.1365-2788.2008.01106.x.